Egypt, Sohag (2019)
|
Sample size
|
4078 |
|
Response rate
|
98.9% |
|
RAAB version
|
RAAB6 |
|
Diabetic retinopathy
|
Yes |
|
Disability module
|
No |
Vision impairment
Prevalence (age-sex adjusted)
|
Female
|
Male
|
Total
|
|||||||
|
|
Extrapolated magnitude
|
%
|
95% CI
|
Extrapolated magnitude
|
%
|
95% CI
|
Extrapolated magnitude
|
%
|
95% CI
|
|
Blind
|
20 598
|
6.9
|
5.2 - 8.5
|
16 119
|
4.9
|
3.8 - 6.0
|
36 717
|
5.9
|
4.8 - 6.9
|
|
Severe
|
19 177
|
6.4
|
4.7 - 8.0
|
10 466
|
3.2
|
2.4 - 4.0
|
29 643
|
4.7
|
3.8 - 5.7
|
|
Moderate
|
66 352
|
22.1
|
19.6 - 24.6
|
52 093
|
15.9
|
13.5 - 18.4
|
118 444
|
18.9
|
16.8 - 21.0
|
|
Mild
|
56 793
|
18.9
|
16.9 - 20.9
|
54 660
|
16.7
|
14.6 - 18.8
|
111 453
|
17.8
|
16.1 - 19.4
|
Cataract
Operable cataract prevalence (age-sex adjusted)
|
Female
|
Male
|
Total
|
|||||||
|
|
Extrapolated magnitude
|
%
|
95% CI
|
Extrapolated magnitude
|
%
|
95% CI
|
Extrapolated magnitude
|
%
|
95% CI
|
|
<3/60
|
4 304
|
1.4
|
0.7 - 2.2
|
3 179
|
1.0
|
0.5 - 1.4
|
7 484
|
1.2
|
0.8 - 1.6
|
|
<6/60
|
9 241
|
3.1
|
2.1 - 4.1
|
5 515
|
1.7
|
1.1 - 2.3
|
14 756
|
2.4
|
1.8 - 2.9
|
|
<6/18
|
26 381
|
8.8
|
7.0 - 10.5
|
19 207
|
5.9
|
4.5 - 7.2
|
45 589
|
7.3
|
6.1 - 8.5
|
|
<6/12
|
36 697
|
12.2
|
10.2 - 14.2
|
30 277
|
9.3
|
7.4 - 11.1
|
66 973
|
10.7
|
9.1 - 12.2
|
Cataract surgical coverage (CSC) (age-sex adjusted)
|
Female
|
Male
|
Total
|
|||||||
|
|
|
%
|
95% CI
|
|
%
|
95% CI
|
|
%
|
95% CI
|
|
CSC<3/60
|
-
|
90.3
|
85.9 - 94.8
|
-
|
89.2
|
85.5 - 85.5
|
-
|
89.9
|
87.3 - 93.3
|
|
CSC<6/60
|
-
|
82.1
|
77.1 - 87.1
|
-
|
83.9
|
79.7 - 88.1
|
-
|
82.8
|
78.8 - 85.5
|
|
CSC<6/18
|
-
|
64.2
|
58.8 - 69.6
|
-
|
64.7
|
59.5 - 70.0
|
-
|
64.4
|
60.3 - 68.1
|
|
CSC<6/12
|
-
|
57.5
|
52.2 - 62.8
|
-
|
56.3
|
50.9 - 61.6
|
-
|
56.9
|
53.6 - 61.4
|
Effective cataract surgical coverage (eCSC) (age-sex adjusted)
The RAAB research team did a formal analysis of eCSC with the World Health Organization and the Vision Loss Expert Group in late 2022. eCSC results will be available on the repository in 2023.
Refractive error
Vision impairing refractive error is defined as presenting VA less than 6/12 improving to 6/12 with pinhole. Use of presenting VA accounts for the prevalence of uncorrected or undercorrected refractive error only.
Vision impairing refractive error prevalence (age-sex adjusted)
|
Female
|
Male
|
Total
|
|||||||
|
|
Extrapolated magnitude
|
%
|
95% CI
|
Extrapolated magnitude
|
%
|
95% CI
|
Extrapolated magnitude
|
%
|
95% CI
|
|
Blind
|
0
|
0.0
|
0.0 - 0.0
|
169
|
0.1
|
0.0 - 0.1
|
169
|
0.0
|
0.0 - 0.1
|
|
Severe
|
0
|
0.0
|
0.0 - 0.0
|
461
|
0.1
|
0.0 - 0.3
|
461
|
0.1
|
0.0 - 0.2
|
|
Moderate
|
11 612
|
3.9
|
2.6 - 5.1
|
6 653
|
2.0
|
1.4 - 2.7
|
18 265
|
2.9
|
2.2 - 3.7
|
|
Mild
|
32 842
|
10.9
|
9.0 - 12.9
|
29 580
|
9.0
|
7.4 - 10.7
|
62 422
|
9.9
|
8.5 - 11.4
|
Effective refractive error coverage (eREC) (age-sex adjusted)
The RAAB research team did a formal analysis of eREC with the World Health Organization and the Vision Loss Expert Group in late 2022. eREC results will be available on the repository in 2023.
Notes
Vision impairment categories defined according to WHO thresholds using presenting visual acuity in the better eye.
All prevalence and coverage estimates are adjusted to the age and gender distribution of the population 50 years and older in the survey area.
All 95% confidence intervals adjusted to account for the cluster design of the survey.